Literature DB >> 33221366

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.

P Fenaux1, D Haase2, V Santini3, G F Sanz4, U Platzbecker5, U Mey6.   

Abstract

Entities:  

Keywords:  Clinical Practice Guidelines; Myelodysplastic syndromes; diagnosis; follow-up; treatment

Mesh：

Year:  2020        PMID： 33221366     DOI： 10.1016/j.annonc.2020.11.002

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

1.  Have we reached a molecular era in myelodysplastic syndromes?

Authors:  Maria Teresa Voso; Carmelo Gurnari
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures.

Authors:  Bruno Fattizzo; Marta Bortolotti; Juri Alessandro Giannotta; Dario Consonni; Silvia Cantoni; Wilma Barcellini
Journal:  Sci Rep       Date:  2022-05-11       Impact factor: 4.996

3.  Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Authors:  Michael Leisch; Michael Pfeilstöcker; Reinhard Stauder; Sonja Heibl; Heinz Sill; Michael Girschikofsky; Margarete Stampfl-Mattersberger; Christoph Tinchon; Bernd Hartmann; Andreas Petzer; Martin Schreder; David Kiesl; Sonia Vallet; Alexander Egle; Thomas Melchardt; Gudrun Piringer; Armin Zebisch; Sigrid Machherndl-Spandl; Dominik Wolf; Felix Keil; Manuel Drost; Richard Greil; Lisa Pleyer
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

4.  Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.

Authors:  Guillermo Garcia-Manero; Ghulam J Mufti; Pierre Fenaux; Rena Buckstein; Valeria Santini; María Díez-Campelo; Carlo Finelli; Osman Ilhan; Mikkael A Sekeres; Amer M Zeidan; Rodrigo Ito; Jennie Zhang; Anita Rampersad; Daniel Sinsimer; Jay T Backstrom; Uwe Platzbecker; Rami S Komrokji
Journal:  Blood       Date:  2022-01-27       Impact factor: 22.113

5.  EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes.

Authors:  Arjan A van de Loosdrecht; Inga Mandac Smoljanović
Journal:  Hemasphere       Date:  2022-02-24

6.  Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report.

Authors:  Hai-Ping Liang; Xing-Chun Luo; Ya-Li Zhang; Bei Liu
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.337

7.  Clinical practice for outpatients that are chronically red cell dependent: A survey in the Netherlands.

Authors:  Rik P B Tonino; Martin R Schipperus; Jaap Jan Zwaginga
Journal:  Vox Sang       Date:  2021-12-12       Impact factor: 2.996

8.  Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).

Authors:  Axel Rüfer; Hubert Angermann; Rudolf Benz; Nicolas Bonadies; Antonello Calderoni; Nathan Cantoni; Anna Efthymiou; Robert Escher; Geneviève Favre; Dorothea Friess; Andreas Gschwend; Andreas Himmelmann; Andreas Holbro; Peter Keller; Eirini Kouroupi; Thomas Lehmann; Nikolaus Pedarnig; Véronique Rigamonti; Kaveh Samii; Adrian Schmidt; Hans-Peter Schäfer; Roland Sperb; Georg Stüssi; Annette Winkler; Reinhard Zenhäusern; Jeroen S Goede
Journal:  Hemasphere       Date:  2022-06-17

Review 9.  Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies.

Authors:  Ibolya Czegle; Austin L Gray; Minjing Wang; Yan Liu; Jun Wang; Edina A Wappler-Guzzetta
Journal:  Life (Basel)       Date:  2021-12-07

10.  Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro.

Authors:  Zheng Li; Jian Zhang; Min Zhou; Jin-Li Li; Qiao-Cheng Qiu; Jian-Hong Fu; Sheng-Li Xue; Hui-Ying Qiu
Journal:  Oncol Rep       Date:  2022-02-01       Impact factor: 3.906
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.